Sequenex Renews ISO 13485:2016 Quality Management System Certification
Sequenex Renews ISO 13485:2016 Quality Management System Certification
Renewal strengthens Sequenex’s position as an integrated software product development partner for the medical device industry
Sequenex Corp. today announced the renewal of its ISO 13485:2016 quality management system certification. The certification is valid through July 9, 2029, and covers Sequenex’s quality management system for the “Design and Development of Software for use in Medical Devices.”
ISO 13485:2016 is an internationally recognized quality management system standard for organizations involved in the design, development and manufacture of medical devices and related services.
Sequenex first achieved ISO 13485:2016 certification in 2023 and has maintained its certification continuously. The renewal follows an independent assessment of the company’s quality management system and confirms its continued conformity with the requirements of the standard.
“Medical device software requires more than working code,” said John Krlin, chief technology officer of Sequenex. “Requirements, risks, design decisions, changes and test evidence must remain connected throughout the software lifecycle. Our renewed certification reflects the quality management foundation that enables us to maintain that discipline.”
Software increasingly shapes how medical devices connect, exchange data and support clinical workflows. Sequenex helps medical device companies address this need by combining specialized engineering, development under the controls of its ISO 13485-certified quality management system, and software lifecycle documentation designed to support customers’ Design History Files and regulatory activities.
“Hardware-focused medical device companies need a software partner that understands the complete product—not simply an engineering vendor,” said Amy Neckermann, chief executive officer of Sequenex. “We bring engineering, quality processes and documentation together so customers can advance their software and device in parallel while reducing gaps, rework and development risk.”
Sequenex works closely with customers and their quality teams to define the software lifecycle documentation appropriate to each program, which may include requirements, design documentation, risk management inputs, traceability, verification and validation evidence, and release documentation.
About Sequenex
Sequenex accelerates software delivery for connected medical devices, wearables, biosensors, CGM and SaMD through custom development, the NEX™ prebuilt software platform and medtech-focused engineering resourcing. Its ISO 13485-certified quality management system and software lifecycle documentation support help customers reduce development time, rework and risk from proof of concept through commercialization.
For more information, visit https://sequenex.com.
Amy Neckermann
Sequenex Corp.
amy@sequenex.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20260902889259/en/
The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
What’s Ahead for Stocks This Quarter—and Where to Invest
Are TIPS ETFs the Best Way to Fight Inflation?
33 Undervalued Stocks to Buy Before the Market Shifts Again
5 Stocks to Sell for Tax-Loss Harvesting
United States